Carbapenem-resistant Enterobacteriaceae Infection Market Research Report present a detailed analysis of the market listing Carbapenem-resistant Enterobacteriaceae Infection Epidemiology, Drug therapies and pipeline for study period from 2018-2030.

Carbapenem-resistant Enterobacteriaceae Infection Market Size, Share | Carbapenem-resistant Enterobacteriaceae Infection Market Research Report, Market Analysis, Market Growth, trends and For...

1. Key Insights2. Report Introduction3. CRE Infections Market Overview at a Glance3.1. Market Share (%) Distribution of CRE Infections in 20183.2. Market Share (%) Distribution of CRE Infections in 20304. Executive Summary of Carbapenem-resistant Enterobacteriaceae5. Disease Background and Overview5.1. Introduction5.2. Enterobacteriaceae5.3. Classification of Carbapenem-resistant Enterobacteriaceae5.4. Risk and Spread of CRE Infection5.5. Mechanism of Drug Resistance5.6. Symptoms5.7. Diagnosis5.8. Treatment for CRE Infections5.9. Guidelines6. Organizations contributing toward the fight against CRE Infections7. Patient Journey8. Case Study9. Epidemiology and Patient Population9.1. Key Findings9.2. Epidemiology of CRE Infections9.3. 7MM Total Incident Cases of CRE9.4. The United States9.4.1.Total Incident Cases of CRE in the United States9.5. EU59.5.1.Germany9.5.1.1.Total Incident Cases of CRE in Germany9.5.2.France9.5.2.1.Total Incident Cases of CRE in France9.5.3.Italy9.5.3.1.Total Incident Cases of CRE in Italy9.5.4.Spain9.5.4.1.Total Incident Cases of CRE in Spain9.5.5.United Kingdom9.5.5.1. Total Incident Cases of CRE in the United Kingdom9.6. Japan9.6.1.Total Incident Cases of CRE in Japan10. Marketed Products10.1. Key cross competition10.2. Vabomere (meropenem/vaborbactam): Deerfield Management Company10.2.1. Product Description10.2.2. Regulatory Milestone10.2.3. Other developmental activities10.2.4. Safety and Efficacy10.2.5. Side Effects10.2.6. Product Profile10.3. Zemdri (Plazomicin): Cipla10.3.1. Drug Description10.3.2. Regulatory Milestone10.3.3. Other development activities10.3.4. Safety and Efficacy10.3.5. Side Effects10.3.6. Product Profile10.4. Recarbrio (Imipenem, cilastatin, and relebactam): Merck10.4.1. Product Description10.4.2. Regulatory Milestone10.4.3. Other Development Activities10.4.4. Safety and Efficacy10.4.5. Side Effects10.4.6. Product Profile10.5. Zavicefta/Avycaz (ceftazidime-avibactam): Pfizer/AbbVie10.5.1. Drug Description10.5.2. Regulatory Milestone10.5.3. Other Development Activity10.5.4. Safety and Efficacy10.5.5. Side Effects10.5.6. Product Profile10.6. Fetcroja (Cefideroco): Shionogi10.6.1. Product Description10.6.2. Regulatory Milestone10.6.3. Other Development Activities10.6.4. Safety and Efficacy10.6.5. Side Effects10.6.6. Product Profile10.7. Zerbaxa (ceftolozane/tazobactam): Merck10.7.1. Product Description10.7.2. Regulatory Milestone10.7.3. Other Development Activity10.7.4. Safety and Efficacy10.7.5. Side Effects10.7.6. Product Profile10.8. Xerava (eravacycline): La Jolla10.8.1. Product Description10.8.2. Regulatory Milestone10.8.3. Other Development Activity10.8.4. Safety and Efficacy10.8.5. Side Effects10.8.6. Product Profile11. Emerging Therapies11.1. Key Cross of Emerging Drugs11.2. WCK 5222 (Zidebactam/Cefepime): Wockhardt11.2.1. Drug Description11.2.2. Other development activities11.2.3. Safety and Efficacy11.2.4. Product Profile11.3. WCK 4282 (Cefepime/Tazobactam): Wockhardt11.3.1. Drug Description11.3.2. Other development activities11.3.3. Clinical Development11.3.4. Clinical trial information11.3.5. Product Profile11.4. ATM-AVI (Aztreonam/avibactam): Pfizer/AbbVie11.4.1. Drug Description11.4.2. Clinical Development11.4.3. Clinical trial information11.4.4. Product Profile11.5. Cefepime/Taniborbactam: Venatorx Pharmaceuticals11.5.1. Drug Description11.5.2. Other development activities11.5.3. Clinical Development11.5.4. Safety and Efficacy11.5.5. Clinical trial information11.5.6. Product Profile12. Other Assets in Development12.1. Key cross: Other Assets12.2. BOS-228: Boston Pharmaceuticals12.2.1. Drug Description12.2.2. Other development activities12.2.3. Product Profile12.3. Nacubactam: Fedorapharma/Meiji Seika Pharma/Hoffmann-La Roche12.3.1. Drug Description12.3.2. Other development activities12.3.3. Product Profile13. Carbapenem-resistant Enterobacteriaceae (CRE): Seven Major Market Analysis13.1. Key Findings13.2. Market Outlook13.2.1. Total Market Size of CRE in 7MM13.2.2. United States Market Size13.2.3. Total Market Size of CRE in the United States13.2.4. Market Size of CRE by Therapies in the United States13.2.5. EU-5 Market Size13.2.6. Germany13.2.6.1. Total Market size of CRE in Germany13.2.6.2. Market Size of CRE by Therapies in Germany13.2.7. France13.2.7.1. Total Market size of CRE in France13.2.7.2. Market Size of CRE by Therapies in France13.2.8. Italy13.2.8.1. Total Market size of CRE in Italy13.2.8.2. Market Size of CRE by Therapies in Italy13.2.9. Spain13.2.9.1. Total Market size of CRE in Spain13.2.9.2. Market Size of CRE by Therapies in Spain13.2.10. United Kingdom13.2.10.1. Total Market size of CRE in the United Kingdom13.2.10.2. Market Size of CRE by Therapies in the United Kingdom13.2.11. Japan13.2.12.Total Market size of CRE in Japan13.2.13. Market Size of CRE by Therapies in Japan14. KOL Views15. Market Access16. Unmet Needs17. Market Barriers18. Market Drivers19. SWOT Analysis20. Appendix20.1. Bibliography21. Report Methodology22. DelveInsight Capabilities23. Disclaimer24. About DelveInsight

Carbapenem-resistant Enterobacteriaceae Infection- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s Carbapenem-resistant Enterobacteriaceae Infection Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease..